ESTTA Tracking number:

ESTTA473128 05/17/2012

Filing date:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Proceeding	92052897
Party	Plaintiff Thomas Sköld
Correspondence Address	ARTHUR E JACKSON MOSER IP LAW GROUP 1030 BROAD STREET, SUITE 203 SHREWSBURY, NJ 07702 UNITED STATES docketing@mtiplaw.com
Submission	Motion for Summary Judgment
Filer's Name	Arthur E Jackson
Filer's e-mail	ajackson@mtiplaw.com, docketing@mtiplaw.com
Signature	/Arthur E Jackson/
Date	05/17/2012
Attachments	TransmittalPetitionExhibits.pdf (2 pages)(64276 bytes) Confidential ExhibitstoComplaint_Redacted PUBLIC2.pdf (64 pages)(2914595 bytes)

PUBLIC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

In the Matter of Registration Nos. 2985751; and 3394514

Dated: August 16, 2005 & March 11, 2008, Respectively

Thomas Sköld,)	
Petitioner,)	
)	
v.)	
) Cancellation No. 92052	897
Galderma Laboratories, Inc.,)	
Registrant)	
)	

TRANSMITTAL OF PETITION EXHIBITS

Because a Protective Order was not in place at the time the Petition and the Amended Petition were filed, certain exhibits were not provided to the Board. Attached hereto are those exhibits as follows:

- 1. Exhibits 2-5, 7, 10 and 11, PUBLIC version; and
- 2. Exhibits 2 5, 7, 10 and 11, TRADE SECRET/COMMERCIALLY SENSITIVE version (under separate cover).

The redactions made in the PUBLIC version were made out of an excess of caution given that the lead proponent of confidentiality is believed to be the Registrant. Petitioner does not oppose putting any part of these documents into the public record. Registrant may wish to (a) file its own revised PUBLIC version or (b) provide the undersigned with designations of confidentiality, and he will file an appropriate revised PUBLIC version.

Respectfully submitted,

Date: May 17, 2012

Arthur E. Jaokson, Esq.

New Jersey Bar No. 00288-1995

ajackson@moseriplaw.com

MOSER TABOADA

1030 Broad Street, Suite 203

Shrewsbury, NJ 07702

(732) 935-7100

(732) 935-7122

Attorney for Petitioner

PUBLIC IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Thomas Sköld,)
Petitioner,)
)
V.)
) Cancellation No. 92052897
Galderma Laboratories, Inc.,)
Registrant)
)

CERTIFICATE OF SERVICE

I hereby certify that a copy of the foregoing Transmittal of Petition Exhibits, and the PUBLIC attachments thereto was sent by email on this $17^{\rm th}$ of May, 2012 to:

Jeff.Becker@haynesboone.com

I hereby certify that a copy of the foregoing Transmittal of Petition Exhibits, and the TRADE SECRET/COMMERCIALLY SENSITIVE attachments thereto was sent first class mail, postage pre-paid on this 17th of May, 2012 to:

Attn: JEFFREY M. BECKER HAYES AND BOONE, LLP 2323 VICTORY AVENUE, SUITE 700 DALLAS, TX 75219 UNITED STATES

Arthur E. Jackson

Exhibit 2 (2002 Agreement)

CONFIDENTIAL

Sköld v. Galderma Cancellation No. __ Re Registration Nos. 2985751 and 3394514

CO-OPERATION, DEVELOPMENT AND LICENSING AGREEMENT

THIS AGREEMENT ("the Agreement") is made and effective the 11th day of February, 2002 by and between:-

 COLLAGENEX PHARMACEUTICALS INC., a company organised and existing under the laws of the State of Delaware, United States of America and having its principal place of business at 41 University Drive, Newtown, Pennsylvania 18940, United States of America (hereinafter "CollaGenex");

and


- THOMAS SKOLD, a citizen and resident of Sweden of Bjorno Gard, S-761 41 Norrtalje, Sweden (hereinafter "Skold").
- (A) WHEREAS Skold is developing, will continue to develop and has rights to the Technology (as defined hereafter) and the potential Products (as defined hereafter) resulting there from and desires to develop said technology in conjunction with CollaGenex in accordance with the terms and conditions hereof; and
- (B) WHEREAS CollaGenex is desirous to participate in and control the development of the technology as defined herein and to obtain all rights thereto in accordance with the terms and conditions hereof;


NOW, THEREFORE, in consideration of the premises and mutual covenants and agreements hereinafter contained, the parties hereto, intending to be legally bound, hereby undertake and agree as follows:-

DEFINITIONS

- 1.1. The term "Affiliate" shall mean any entity in which the party has a direct or indirect equity interest or income interest ownership of at least fifty per cent (50%) or more, or any entity which, directly or indirectly, through one or more intermediaries, controls or is controlled by, or is under common control with the party.
- 1.2. The term "Confidential Information" shall mean any and all information or any portion thereof howsoever disclosed to or otherwise acquired or observed by either party or its employees, agents or Affiliates (each individually referred to as a "Recipient") either directly or indirectly from the other party, including, but not limited to, the technology and/or the products resulting there from as defined herein, enhancements, modifications, discoveries, claims, formulae, processes, apparatuses, research, development, patents, Confidential Information, Know-how as defined herein, trade secrets, knowledge, designs, specifications, drawings, concepts, data, reports, methods, documentation, methodology, pricing, marketing and sales plans, customer lists, collaborators, salaries or business affairs and any other information or knowledge owned or developed or controlled by either party except for information which the Recipient can demonstrate:-
 - (a) was at the time of disclosure to such Recipient part of the public domain or thereafter becomes part of the public domain through no act or omission by such Recipient; or
 - (b) was lawfully in such Recipient's possession as evidenced by written records prior to disclosure by the disclosing party and without any obligation of confidentiality; or

- (c) was lawfully received by such Recipient after disclosure from a third party without obligation of confidentiality and without violation by said third party of any obligation of confidentiality to another party; or
- (d) was required to be disclosed by law or court order; or
- (e) was independently developed by the Recipient without reference to or reliance on any of the Confidential Information.





GRANT OF RIGHTS 2.





2.2.



records, ledgers, books and laboratory to verify Skold's compliance with the terms of this Agreement.

2.4. 2.5.


3. PAYMENTS FOR RIGHTS

3.1.



i.

jji.











- (c) all payments by CollaGenex to Skold will be in United States dollars.
- (d)
- (e)













4. INTELLECTUAL PROPERTY

4.1. Patents











7



4.2. Trade Marks

- 4.2.1. 4.2.2. 4.2.3.
- 5, REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PARTIES
- 5.1. CollaGenex represents and warrants to Skold that:-
 - CollaGenex Pharmaceuticals, Inc. is a corporation duly organised, validly (a) existing and in good standing under the laws of the State of Delaware, United States of America and that it has full corporate power and authority to conduct the business in which it is now engaged and as contemplated by this Agreement; and









- 5.2. Skold hereby warrants and represents to CollaGenex that:-
 - (a) he is a citizen and resident of Sweden and in good standing in that country; and



6. INSURANCE



THOMAS O ANNE BJÖRNÖ



MARKETING AUTHORISATIONS



CONFIDENTIALITY



8.2.



8.3. The parties acknowledge and agree that the financial terms contained in this Agreement shall be considered as Confidential Information hereunder.



TERM AND TERMINATION AND REVERSION OF RIGHTS 9.





11



10. FORCE MAJEURE



11. OTHER PROVISIONS

11.1. 11.2.

12

Any notice shall be deemed to have been given on day of delivery or receipt. Notices shall be delivered to the parties at the following addresses until a different address has been designated, by notice, to the other party:-

If to CollaGenex

CollaGenex Pharmaceuticals, Inc.,

41 University Drive, Suite 200,

Newtown,

Pennsylvania 18940, United States of America. Telefax: (001) 215 579 8577 Attention: Senior Vice President

If to Skold

Thomas Skold, Bjorno Gard, S-761 41 Norrtalje,

Sweden.

Telefax: (0046) 176 22 4420

11.3. This Agreement is executed in two counterparts each one of which is deemed an original and which taken together shall constitute one and the same instrument.



11.11. Except where the context otherwise permits or requires, words denoting the singular include the plural and vice versa; wording denoting one gender include all genders; words denoting persons include firms and corporations and vice versa.



IN WITNESS WHEREOF, THE PARTIES HAVE CAUSED THIS AGREEMENT TO BE SIGNED BY THEIR DULY AUTHORISED REPRESENTATIVES THE DAY AND YEAR FIRST ABOVE WRITTEN:

COLLAGENEX PHARMACEUTICALS, INC.

Brian M. Gallagner Ph.D.,

Chairman, President & Chief Executive Officer

THOMAS SKOLD

Exhibit 3 (2004 Agreement)

CONFIDENTIAL

Sköld v. Galderma Cancellation No. __ Re Registration Nos. 2985751 and 3394514

THOMAS O ANNE BJÖRNÖ

SIDA 02/28

ASSET PURCHASE AND PRODUCT DEVELOPMENT AGREEMENT

by and between

COLLAGENEX PHARMACEUTICALS INC.

and

THOMAS SKOLD

Dated as of August 19, 2004

TABLE OF CONTENTS

		Page
ARTICLE 1	DEFINITIONS	1
ARTICLE		6
2.1		6
2.2		6
2.3		7
2.4		7
2.5		7
2.6		7
ARTICLE 3		
		8
3.1 •		8
3.2		9
3.3		10
3.4		10
3.5		10
3.6		10
3.7		
ARTICLE 4		11
4.1		11
4.2		11
4.3 4.4		12
4.4		12
4.6		12
4.7		12
4.7		12
ARTICLE 5	DEDDECEMENT TIONS WARD AND TO SOME THE CONTRACTOR	13
5.1	REPRESENTATIONS, WARRANTIES AND COVENANTS	
5.2		14
5.3		14
5.5		15

TABLE OF CONTENTS

(continued)

	Page
ARTICLE 6	CONFIDENTIALITY, PUBLICATION AND PUBLIC ANNOUNCEMENTS15
6.1	. 15
6.2	. 16
6.3	16
6.4	16
6.5	16
6.6	16
ARTICLE 7	. 17
7.1	. 17
7.2	. 17
7.3	. 17
7.4	. 18
7.5	. 19
ARTICLE 8	TERM AND TERMINATION19
8.1	19
8.2	19
8.3	19
8.4	19
8.5	20
ARTICLE 9	MISCELLANEOUS21
9.1	21
9.2	Assignment
9.3	Further Actions
9.4	Force Majeure
9.5 9.6	Notices
9.6	Amendment
9.7	Counterposts Faccionile Signature
9.8	Counterparts; Facsimile Signatures
7.7	172

THOMAS O ANNE BJÖRNÖ

TABLE OF CONTENTS

(continued)

		Page
9.10	Governing Law	23
	Severability	
	Entire Agreement of the Parties	
	Independent Contractors	
	Expenses	
	No Third Party Beneficiaries	
	No Strict Construction	

ASSET PURCHASE AND PRODUCT DEVELOPMENT AGREEMENT

This ASSET PURCHASE AND PRODUCT DEVELOPMENT AGREEMENT (the "Agreement"), dated as of August 19, 2004 (the "Effective Date"), is made by and between CollaGenex Pharmaceuticals Inc., a Delaware corporation having its principal office at 41 University Drive, Newtown, Pennsylvania, United States of America 18940 ("CollaGenex"), and Thomas Skold, a citizen and resident of Sweden of Bjorno Gard, S-761 41 Norrtalje, Sweden ("Skold"). CollaGenex and Skold are each sometimes referred to individually as a "Party" and together as the "Parties."

RECITALS

WHEREAS, the Parties entered into that certain Co-operation, Development and Licensing Agreement dated February 12, 2002 (the "Original Agreement");

WHEREAS, the Parties desire to modify the terms of their relationship by terminating the Original Agreement and, simultaneously therewith, entering into this Agreement; and

WHEREAS, in connection with such modification of terms, CollaGenex desires to acquire from Skold the topical technology that Skold has developed, as more specifically described herein, and Skold desires to transfer to CollaGenex, such topical delivery technology.

NOW, THEREFORE, in consideration of the foregoing premises and the representations, covenants and agreements contained herein, CollaGenex and Skold, intending to be legally bound, hereby agree as follows:

ARTICLE 1 DEFINITIONS

When used in this Agreement, whether in the singular or plural, each of the following capitalized terms shall have the meanings set forth in this Article 1.

1.1 "Affiliate" means a Person that, directly or indirectly, through one or more intermediates, controls, is controlled by, or is under common control with, the Person specified. For the purposes of this definition, control shall mean the direct or indirect ownership of (i) in the case of corporate entities, securities authorized to cast more than fifty percent (50%) of the votes in any election for directors, (ii) in the case of non-corporate entities, more than fifty percent (50%) ownership interest with the power to direct the management and policies of such non-corporate entity, or (iii) such lesser percentage as may be the maximum percentage allowed to be owned by a foreign corporation under the applicable laws or regulations of a particular jurisdiction outside of the United States) of the equity having the power to vote in the election of directors or to direct the management and policies of another entity. Notwithstanding the foregoing, the term "Affiliate" shall not include subsidiaries in which a Person or its Affiliates owns a majority of the ordinary voting power to elect a majority of the board of directors, but is restricted from electing such majority by contract or otherwise, until such time as such restriction is no longer in effect.


- 1.2 "Books and Records"

 Affiliates related to the Restoraderm
- 1.3 "Additional Records" means any and all records or documentation in whatever
- 1.4 "Business Day" means any day except Saturday and Sunday, on which commercial banking institutions in New York are open for business. Any reference in this Agreement to "day", whether or not capitalized, shall refer to a calendar day, not a Business Day.


1.6 "Confidential Information" means all secret, confidential or proprietary

Notwithstanding the foregoing sentences, Confidential Information shall not include any information or materials that:

- (a) were already known to the Receiving Party (other than under an obligation
 of confidentiality) at the time of disclosure by the Disclosing Party to the extent such Receiving
 Party has documentary evidence to that effect;
- (b) were generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;
- (c) became generally available to the public or otherwise part of the public domain after its disclosure or development, as the case may be, and other than through any act or omission of a Party in breach of such Party's confidentiality obligations under this Agreement; or
- (d) were subsequently lawfully disclosed to the Receiving Party by a Third Party who had no obligation to the Disclosing Party not to disclose such information or materials to others.




are not already refl



1.16 "Person" means any individual, firm, corporation, partnership, limited liability company, trust, unincorporated organization or other entity or a government agency or political subdivision thereto, and shall include any successor (by merger or otherwise) of such Person.


1.17 "<u>Product</u>"
1.18




- 1.25 "Third Party(ies)" means any Person other than Skold, CollaGenex and their respective Affiliates.
- 1.26 "Trademark" or "Trademarks" means all trademarks, service marks, trade names, domain names, and registrations and applications for registration of the foregoing.



ARTICLE 2 PURCHASE AND SALE;



- 2.2 <u>Excluded Assets</u>. Notwithstanding anything to the contrary contained herein.
- (a) books and records that Skold or its Affiliates are required to retain pursuant to any applicable law or regulations, other than the Books and Records; and
- (b) general books of account and books of original entry that comprise Skold's or its Affiliates' permanent accounting or tax records.





Further Assurances. Skold shall execute and deliver (and shall cause its Affiliates 2.4






-7-



3.2 Selection of and Responsibility for Development of Products.








ARTICLE 4
FINANCIAL PROVISIONS




- 10 -

1-PR/1256533.9



4.7 Payment Currency: Currency Exchange. All payments made by CollaGenex to Skold hereunder shall be in United States dollars. With respect to Net Sales invoiced or expenses incurred in U.S. dollars, the Net Sales or expense amounts and the amounts due to Skold hereunder shall be expressed in U.S. dollars. With respect to Net Sales invoiced or expenses incurred in a currency other than U.S. dollars, the Net Sales or expense shall be expressed in the domestic currency of the entity making the sale or incurring the expense, together with the U.S. dollar equivalent, calculated using the arithmetic average of the spot rates on the last Business Day of each month of the calendar quarter in which the Net Sales were made or the expense was incurred. The "closing mid-point rates" found in the "Dollar spot forward

against the Dollar" table published by *The Financial Times*, or any other publication as agreed to by the Parties, shall be used as the source of spot rates to calculate the average as defined in the preceding sentence. All payments shall be made by wire transfer in U.S. dollars to the credit of such bank account as shall be designated at least five (5) Business Days in advance by Skold in writing to CollaGenex.



ARTICLE 5 REPRESENTATIONS, WARRANTIES AND COVENANTS

- 5.1 <u>Mutual Representations, Warranties and Covenants</u>. Each of Skold and CollaGenex hereby represents, warrants and covenants to the other Party as follows:
- (a) It is duly organized and validly existing, or is a citizen and resident, as applicable, and in good standing under the laws of such Party's respective jurisdiction. It has the requisite legal power and authority to conduct its business as presently being conducted and as proposed to be conducted by it and is duly qualified to do business in those jurisdictions where its ownership of property or the conduct of its business requires;



5.2 <u>Additional Representations, Warranties and Covenants of Skold</u>. Skold hereby further represents, warrants and covenants to CollaGenex that:







ARTICLE 6
CONFIDENTIALITY, PUBLICATION AND PUBLIC ANNOUNCEMENTS



- 14 -



- 6.3 Return of Confidential Information. Upon termination of this Agreement, the
- 6.4 <u>Unauthorized Use</u>. If either Party becomes aware or has knowledge of any unauthorized use or disclosure of the other Party's Confidential Information, it shall promptly notify the disclosing Party of such unauthorized use or disclosure.
- 6.5 Public Announcements. Except as set forth in press releases published by



- 16 -

1-PR/1256533.9



- 17 -

1-PR/1256533.9




ARTICLE 8
TERM AND TERMINATION



8.5 <u>Effect of Termination</u>.

- 18 -

21/04/2010 15:40 0176224420 THOMAS O ANNE BJÖRNÖ SIDA 24/28




- 19 -

I-PR/1256533.9



ARTICLE 9 MISCELLANEOUS





9.3 <u>Further Actions</u>. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

9.4 Force Majeure.

9.5 Notices. Notices to Skold shall be addressed to:

Thomas Skold Bjorno Gard S-761 41 Norrtalje Sweden

Facsimile No.: (0046) 176 22 4420

Notices to CollaGenex shall be addressed to:

CollaGenex Pharmaceuticals, Inc. 41 University Drive, Suite 200 Newtown, Pennsylvania 18940 United States of America Attention: Chief Executive Officer


Attention: Chief Executive Officer Facsimile No.: (001) 215 579 8577



- 9.6 <u>Amendment</u>. No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.
- 9.7 <u>Waiver</u>. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.
- 9.8 <u>Counterparts: Facsimile Signatures.</u> This Agreement may be executed in counterparts and such counterparts taken together shall constitute one and the same agreement. This Agreement may be executed by facsimile signatures, which signatures shall have the same force and effect as original signatures.
- 9.9 <u>Descriptive Headings</u>. The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement.



9.11 Severability. If any provision hereof should be held invalid, illegal or



- 9.13 <u>Independent Contractors</u>. The relationship between the Parties created by this Agreement is one of independent contractors and neither Party shall have the power or authority to bind or obligate the other except as expressly set forth in this Agreement.
 - 9.14 Expenses. Unless otherwise provided herein, all costs and expenses incurred in
- 9.15 No Third Party Beneficiaries. No person or entity other than the Parties hereto and their respective Affiliates, successors and permitted assigns shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.
- 9.16 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against either Party.

[Signature Page Immediately Follows]

Exhibit 4 (February 2008 Letter)

CONFIDENTIAL

Sköld v. Galderma Cancellation No. __ Re Registration Nos. 2985751 and 3394514



VIA FEDERAL EXPRESS

12 February 2008

Mr. Thomas F. Clauss, Jr. Wiggin and Dana LLP 400 Atlantic Street P.O. Box 110325 Stamford, CT 06911-0325


Re:

Asset Purchase and Product Development Agreement by and between CollaGenex Pharmaceuticals, Inc. and Thomas Sköld

Dear Mr. Clauss:



CollaGenex Pharmaceuticais, Inc., 41 University Drive, Suite 200, Newtown, PA 18940 USA 215-579-7388 voice 215-579-8577 fax




Intellectual Property Rights, 3.6



Confidential Information, 6.5



History of the Relationship





Summary of CollaGenex's Position





Yours sincerely,

Andrew K.W. Powell VP, General Counsel & Corporate Secretary

cc:

Thomas Sköld (vla e-mail)

Gregory Ford, VP, Business Development & Strategic Planning Ellen E. Fielitz, Director, Intellectual Property

Exhibit 5 November 2009 Letter

CONFIDENTIAL

Sköld v. Galderma Cancellation No. __ Re Registration Nos. 2985751 and 3394514

GALDERMA USA

November 27, 2009

GALDERS'S

LABOSISTORIES, I.P.

Mr. Thomas Skold

Bjorno Gard

14501 H. freeway

SE-761 41 Norrtalje

Sweden

fore Worth,

RE: August 19, 2004 Asset Purchase and Product Development Agreement

76177

Dear Mr. Skold:

Tel: (8:7) 951-5000



Thank you for your attention to this matter.

Best regards,

Quintin Cassady

Vice President and General Corneal

Exhibit 7

(Exhibit B)

CONFIDENTIAL

Sköld v. Galderma Cancellation No. __ Re Registration Nos. 2985751 and 3394514

EXHIBIT B

Trademark Assignment



[ASSIG	NOR]		
By:			
Name:			
Title:			

APPENDIX A




Exhibit 10

(Consulting Agreement)

CONFIDENTIAL

Sköld v. Galderma Cancellation No. 92052897 Re Registration Nos. 2985751 and 3394514

CONSULTING AGREEMENT

THIS CONSULTING SERVICES AGREEMENT (the "Agreement"), is entered into as of August 1, 2004 by and between CollaGenex, Inc. (the "Company"), and Thomas Skold, an individual ("Consultant").


BACKGROUND

The Company wishes to obtain the services of Consultant for certain purposes, and Consultant wishes to provide such services, all subject to the terms and condition of this Agreement.

NOW, THEREFORE, in consideration of the mutual promises hereinafter set forth, and intending to be legally bound hereby, the Company and Consultant hereby agree as follows:




3. Compensation



	(b)	Further	Assurances.	Upon th	ne request	and at the	avnanca	of the
	(c)	Survival	The obligat	tions of C	onoultout d	has been stee		1 10
survive shall surviv paragraph 6.	e termina	ation or ex	. The obligate piration of the	nis Agreer	nent includ	ling the p	rovisions	of this
7.	Term	ination. N	otwithstandi	ng the pro	visions of n	aragraph '	Compan	v mav
							_	
8.	No Co	nflicting	Agreements					

1-PR/1264010.2 3



14. <u>Notices</u>. All notices and other communications required or permitted hereunder or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when hand delivered, sent by facsimile or mailed by registered or certified mail, as follows (provided that notice of change of address shall be deemed given only when received):

If to the Company, to:

CollaGenex Pharmaceuticals, Inc. 41 University Drive, Suite 200 Newtown, Pennsylvania 18940 United States of America Attention: Chief Executive Officer Facsimile No.: (001) 215 579 8577

If to Consultant, to:

Thomas Skold Bjorno Gard S-761 41 Norrtalje Sweden Facsimile No.: (0046) 176 22 4420

or to such other names or addresses as the Company or Consultant, as the case may be, shall designate by notice to each other person entitled to receive notices in the manner specified in this paragraph.

- 15. <u>Counterparts</u>. This Agreement shall become binding when any one or more counterparts hereof, individually or taken together, shall bear the signatures of Consultant and the Company. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original as against any party whose signature appears thereon, but both of which together shall constitute but one and the same instrument.
- 16. <u>Severability</u>. If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or application of this Agreement which can be given effect without the invalid or unenforceable provision or application and shall not invalidate or render unenforceable such provision or application in any other jurisdiction.

[Signature Page Immediately Follows]

IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have duly executed this Agreement as of the date first above written.

COLLAGENEX PHARMACEUTICALS INC.:

By: Name: Colin Stewart

Title: Chief Executive Officer and President

THOMAS SKOLD:

6

1-PR/1264010.2

Exhibit 11

(November 2007 Email Exchange)

CONFIDENTIAL

Sköld v. Galderma Cancellation No. 92052897 Re Registration Nos. 2985751 and 3394514

PUBLIC From: Thomas Sköld [mailto:thomas-skold@telia.com] Från: Greg Ford [mailto:gford@collagenex.com] Sent: Thursday, November 29, 2007 6:03 AM Skickat: den 29 november 2007 23:55 Ämne: RE: Restoraderm Kopia: Andrew Powell Subject: Restoraderm Good moming Greg. Till: Thomas Sköld To: Greg Ford Dear Thomas, All the best, Greg

secrets or privileged or otherwise confidential information. If you received this message in error, or have reason to believe you are not authorized to receive it, please promptly delete This message and any included attachments are from Colla Genex Pharmaceuticals and are intended only for the addressee(s). The information contained herein may include trade

Regards, Thomas